- Home
- MRNS vs TRT Comparison
MRNS vs TRT Comparison
Compare MRNS & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- TRT
- Stock Information
- Founded
- MRNS 2003
- TRT 1958
- Country
- MRNS United States
- TRT United States
- Employees
- MRNS N/A
- TRT N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- TRT Industrial Machinery/Components
- Sector
- MRNS Health Care
- TRT Technology
- Exchange
- MRNS Nasdaq
- TRT Nasdaq
- Market Cap
- MRNS 29.9M
- TRT 24.7M
- IPO Year
- MRNS 2014
- TRT N/A
- Fundamental
- Price
- MRNS $0.54
- TRT $5.85
- Analyst Decision
- MRNS Buy
- TRT
- Analyst Count
- MRNS 12
- TRT 0
- Target Price
- MRNS $4.28
- TRT N/A
- AVG Volume (30 Days)
- MRNS 3.2M
- TRT 8.5K
- Earning Date
- MRNS 03-04-2025
- TRT 02-10-2025
- Dividend Yield
- MRNS N/A
- TRT N/A
- EPS Growth
- MRNS N/A
- TRT N/A
- EPS
- MRNS N/A
- TRT 0.13
- Revenue
- MRNS $31,466,000.00
- TRT $42,145,000.00
- Revenue This Year
- MRNS $14.97
- TRT N/A
- Revenue Next Year
- MRNS $57.65
- TRT N/A
- P/E Ratio
- MRNS N/A
- TRT $45.24
- Revenue Growth
- MRNS 1.63
- TRT 2.10
- 52 Week Low
- MRNS $0.22
- TRT $4.94
- 52 Week High
- MRNS $10.50
- TRT $7.88
- Technical
- Relative Strength Index (RSI)
- MRNS 70.29
- TRT 39.90
- Support Level
- MRNS $0.54
- TRT $5.74
- Resistance Level
- MRNS $0.56
- TRT $6.10
- Average True Range (ATR)
- MRNS 0.02
- TRT 0.20
- MACD
- MRNS 0.01
- TRT 0.02
- Stochastic Oscillator
- MRNS 93.71
- TRT 46.03
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About TRT Trio-Tech International
Trio-Tech International is a provider of third-party semiconductor testing and burn-in services through its laboratories in Southeast Asia. The company operates in four segments namely Manufacturing, Testing services, Distribution, and Real Estate. Its Manufacturing segment manufactures both front-end and back-end semiconductor test equipment and related peripherals. The Testing Services segment renders services to the manufacturer and purchaser of semiconductors and other entities. Its Distribution segment is involved in the distribution of its products. The company's Real Estate segment consists of investment in real estate. Its geographical area of operations includes the United States, Singapore, Malaysia, Thailand, and China. It derives maximum revenue from Testing services Segment.